A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Allergy and Infectious Diseases (NIAID)
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Between 18 and 70 years of age
Body weight under 115 kg (approximately 253 pounds)
Evidence of recently acquiring HIV
Not pregnant or breastfeeding
No recent use of medications to prevent or treat HIV
Able and willing to provide informed consent to study and its procedures which include
* initiating HIV medications (also called antiretroviral treatment or ART) following enrollment,
* A later, monitored pause in HIV medications (also called an analytical treatment interruption, or ATI)
While pausing HIV treatment per study guidelines until resuppressed following treatment restart, agree to using barrier contraception to prevent HIV acquisition in sexual partners
Agree to use effective contraception to prevent pregnancy in oneself and sexual partners who may become pregnant.
Clareo Health | A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
